Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Therapeutic Pipeline Program, 2015
    Screening for Compounds Lowering Alpha-synuclein Expression Using a Novel Cell Line Assay

    Study Rationale:                             
    Multiple lines of evidence suggest that alpha-synuclein gain-of-function is characteristic of Parkinson’s disease (PD). Reduction of alpha-synuclein...

  • Therapeutic Pipeline Program, 2015
    Assay-PoC for the Reduction of Endogenous Alpha-synuclein Levels in iPS-PD Neurons

    Study Rationale:                             
    Accumulation of the alpha-synuclein protein in the brain of individuals with Parkinson’s disease (PD) is a hallmark of the disease, and mutations in the...

  • Therapeutic Pipeline Program, 2015
    Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease

    Study Rationale:
    The alpha-synuclein protein forms oligomers (protein clumps) that cause toxicity in the brains of individuals with Parkinson’s disease (PD). We have developed methods that can measure...

  • Therapeutic Pipeline Program, 2015
    Pharmacokinetics and CNS Distribution of IgG Antibodies: Quantitative Comparison of Blood-brain, Blood-CSF and CSF-brain Relationships After Intranasal and Intravascular Dosing

    Study Rationale:                             
    Immunotherapy using antibodies (large proteins) directed against alpha-synuclein is a promising, potentially disease-modifying treatment approach for...

  • Research Grant, 2015
    Phase IB Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A in Those Who Participated in the AFF008 Program

    Promising Outcomes of Original Grant:
    Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease (PD), and its reduction is expected to positively modify...

  • Therapeutic Pipeline Program, 2015
    The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson’s Disease

    Study Rationale:                             
    Anxiety is a common non-motor symptom among individuals with Parkinson’s disease (PD) and is associated with a reduced quality of life. Despite this...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.